The Chinese company has advanced multiple candidates into late-stage development, including three approved products, QLETLI, POBEVCY and BAT1806 in China. In addition, the company has 25 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody drug conjugates (ADC).

In January 2023, Bio-Thera filed a new drug application (NDA) with China’s National Medical Products Administration (NMPA) to gain approval of what would be the country's first biosimilar of Actemra (tocilizumab).